Jim Cramer Looks At Eli Lilly's Outlook As The Company's Alzheimer Drug Goes Through Fda

Jim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA

CNBC Television

FDA approves a new Alzheimer's drug from Eli Lilly

CNBC Television

FDA rejects Eli Lilly’s accelerated approval application for Alzheimer’s drug

Jim Cramer on how Lilly's Alzheimer's drug compares to Biogen's

CNBC Television

Eli Lilly CEO on FDA approval pathway for Alzheimer's drugs

CNBC Television

Jim Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study results

CNBC Television

FDA advisers say Eli Lilly Alzheimer's treatment is effective

CNBC Television

Eli Lilly CEO discusses FDA's approval of Biogen's new Alzheimer's drug

FDA advisers say Eli Lilly's Alzheimer's treatment is effective

CNBC Television

Eli Lilly testing Alzheimer's drug

Lilly seeks approval for Alzheimer's drug

WTHR

Jim Cramer explains why Eli Lilly will be the winner over Biogen in Alzheimer's fight

CNBC Television

Jim Cramer says there's a buying opportunity in this pharmaceutical company

CNBC Television

Eli Lilly CEO: We see a path to an Alzheimer's disease-modifying drug

CNBC Television

Jim Cramer on FDA resignations connected to the approval of Biogen’s Alzheimer’s drug

CNBC Television

FDA approves new Alzheimer’s drug

Good Morning America

Promising data from Eli Lilly shows a significant slowdown in the pace of Alzheimer's

CNBC Television

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer

CNBC Television

Eli Lilly may have developed the greatest drug of all time, says Jim Cramer

CNBC Television

Cramer's First Take: Eli Lilly's Alzheimer's drug is 'the holy grail'

CNBC Television